Peptide Initiative

Peptides · Peptide comparison

Lactoferricin B vs LL-37

A 25-amino-acid antimicrobial peptide fragment derived from bovine lactoferrin by pepsin cleavage, featuring a twisted antiparallel beta-sheet structure with broad-spectrum bactericidal activity, anti-biofilm properties, and emerging anticancer potential through selective membrane disruption mediated by the critical RRWQWR motif

Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeLactoferricin B1–10 mgLL-371.6–1.6 mg/mL
FrequencyLactoferricin BMultiple times dailyLL-37Once daily
AdministrationLactoferricin BOral (research — resistant to gastric digestion)LL-37Topical application (wound healing)
Cycle lengthLactoferricin B4-6 weeksLL-3712+ weeks
Onset speedLactoferricin BRapid (hours to days)LL-37Moderate (1-2 weeks)
Evidence levelLactoferricin BModerate human trials (Phase 1-2)LL-37Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Germs

Lactoferricin B94%
LL-37No recorded rating

Cancer Cell Targeting

Lactoferricin B86%
LL-37No recorded rating

Immune Support

Lactoferricin B82%
LL-37No recorded rating

Wound Healing

Lactoferricin BNo recorded rating
LL-3794%

Fighting Infections

Lactoferricin BNo recorded rating
LL-3791%

Immune Boost

Lactoferricin BNo recorded rating
LL-3787%

Technical data

Compound specifications

Lactoferricin B

Molecular formula
Approximately C142H224N46O34S2 (varies slightly by reported sequence)
Molecular weight
~3,126 Da (25-amino-acid bovine lactoferricin B)
Half-life
Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance
Bioavailability
Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism
CAS number
146897-68-9

LL-37

Molecular formula
C205H340N60O53
Molecular weight
4,493.26 Da
Half-life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS number
154947-66-7

Protocols

Dosing compared

Lactoferricin B

No dose levels recorded.

LL-37

Topical

  • 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
  • 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Applications

Best suited for

Lactoferricin B

Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

LL-37

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].

Safety profile

Side effects

Lactoferricin B

Common

  • Mild GI discomfort
  • Bitter taste
  • Local irritation (topical use)
  • Mild flatulence

Uncommon

  • Allergic reaction in milk-sensitive individuals

Serious

  • Hemolytic activity at high concentrations

LL-37

Common

  • Local site irritation
  • Transient stinging or burning
  • Mild perilesional erythema
  • Increased wound exudate

Uncommon

  • Allergic contact reaction

Serious

  • Hemolytic activity at systemic concentrations

Research status

Safety & evidence

Lactoferricin B

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Lactoferricin B is a 25-amino acid peptide fragment of bovine lactoferrin, a protein found in cow's milk [2]. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations.

Contraindications

  • Known allergy to bovine milk proteins or lactoferrin — cross-reactivity possible
  • Pregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation
  • Active hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis
  • Iron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule

LL-37

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

Contraindications

  • Known hypersensitivity to cathelicidin peptides or formulation components
  • Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
  • Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
  • Severe renal impairment — peptide clearance may be altered

Decision guide

Which is right for you?

Lactoferricin B

Choose Lactoferricin B if…

  • Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
  • Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
  • Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
  • Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion

LL-37

Choose LL-37 if…

  • Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
  • Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
  • Anti-biofilm strategies for chronic wound infections and medical device-associated infections
  • Boosting innate immune defense in immunocompromised or aging individuals